MA31315B1 - Utilisation d'une composition comprenant du formotérol et du beclometasone dipropionate de béclométasone pour la prévention et/ou le traitement d'une exacerbation de l'asthme - Google Patents
Utilisation d'une composition comprenant du formotérol et du beclometasone dipropionate de béclométasone pour la prévention et/ou le traitement d'une exacerbation de l'asthmeInfo
- Publication number
- MA31315B1 MA31315B1 MA32284A MA32284A MA31315B1 MA 31315 B1 MA31315 B1 MA 31315B1 MA 32284 A MA32284 A MA 32284A MA 32284 A MA32284 A MA 32284A MA 31315 B1 MA31315 B1 MA 31315B1
- Authority
- MA
- Morocco
- Prior art keywords
- beclomethasone
- asthma
- composition
- formoterol
- prevent
- Prior art date
Links
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 title abstract 2
- 229950000210 beclometasone dipropionate Drugs 0.000 title abstract 2
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 title abstract 2
- 229960002848 formoterol Drugs 0.000 title abstract 2
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 title 1
- 229940092705 beclomethasone Drugs 0.000 title 1
- 208000006673 asthma Diseases 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000023819 chronic asthma Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000024710 intermittent asthma Diseases 0.000 abstract 1
- 238000009115 maintenance therapy Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention porte sur l'utilisation d'une composition comprenant une combinaison fixe a) de formotérol, d'un sel ou solvate pharmaceutiquement acceptable de celui-ci ou d'un solvate d'un tel sel; et b) de dipropionate de béclométasone. La composition sert à fabriquer un médicament pour prévenir et/ou traiter une crise d'asthme, d'asthme intermittent et/ou d'épisodes d'asthme chronique pendant la thérapie d'entretien de l'asthme ; la même composition pour servir à soulager l'asthme symptomatique, si nécessaire.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07007930A EP1982709A1 (fr) | 2007-04-19 | 2007-04-19 | Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme |
| PCT/EP2008/003012 WO2008128685A1 (fr) | 2007-04-19 | 2008-04-16 | Utilisation d'une composition comprenant du formotérol et du dipropionate de béclométasone pour la prévention et/ou le traitement d'une crise d'asthme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA31315B1 true MA31315B1 (fr) | 2010-04-01 |
Family
ID=38458097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA32284A MA31315B1 (fr) | 2007-04-19 | 2009-10-15 | Utilisation d'une composition comprenant du formotérol et du beclometasone dipropionate de béclométasone pour la prévention et/ou le traitement d'une exacerbation de l'asthme |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20080261932A1 (fr) |
| EP (3) | EP1982709A1 (fr) |
| JP (2) | JP5492072B2 (fr) |
| KR (3) | KR20100014408A (fr) |
| CN (1) | CN101657191B (fr) |
| AU (1) | AU2008241045C1 (fr) |
| BR (1) | BRPI0809800A2 (fr) |
| CA (1) | CA2684539A1 (fr) |
| CO (1) | CO6220945A2 (fr) |
| CY (1) | CY1117568T1 (fr) |
| DK (1) | DK2146704T3 (fr) |
| EA (1) | EA018589B1 (fr) |
| ES (2) | ES2568497T3 (fr) |
| GE (1) | GEP20145999B (fr) |
| HR (1) | HRP20160588T1 (fr) |
| HU (1) | HUE029263T2 (fr) |
| IL (1) | IL201632A (fr) |
| MA (1) | MA31315B1 (fr) |
| ME (1) | ME00945B (fr) |
| MX (1) | MX2009010851A (fr) |
| MY (1) | MY169579A (fr) |
| NZ (1) | NZ580526A (fr) |
| PL (2) | PL3034073T3 (fr) |
| RS (1) | RS54874B1 (fr) |
| SI (1) | SI2146704T1 (fr) |
| TN (1) | TN2009000390A1 (fr) |
| TR (1) | TR201909857T4 (fr) |
| UA (1) | UA100237C2 (fr) |
| WO (1) | WO2008128685A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1982709A1 (fr) | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme |
| RS53514B1 (sr) * | 2009-10-02 | 2015-02-27 | Chiesi Farmaceutici S.P.A. | Farmaceutske aerosolne formulacije od formoterola i beklometazon dipropionata |
| CN102247597B (zh) * | 2010-05-19 | 2015-01-07 | 天津金耀集团有限公司 | 一种糖皮质激素与支气管扩张剂的吸入剂 |
| MX368199B (es) * | 2012-01-25 | 2019-09-24 | Chiesi Farm Spa | Formulación en polvo seco que comprende un corticoesteroide y un beta-adrenérgico para administración por inhalación. |
| US11052202B2 (en) * | 2012-11-07 | 2021-07-06 | Chiesi Farmaceutici S.P.A. | Drug delivery device for the treatment of patients with respiratory diseases |
| AU2017328908B2 (en) * | 2016-09-19 | 2020-04-02 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| CN107233311B (zh) * | 2017-06-27 | 2020-12-04 | 长风药业股份有限公司 | 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法 |
| AU2019282562A1 (en) * | 2018-06-04 | 2021-01-21 | Lupin Inc. | Stable pharmaceutical compositions for pressurized metered dose inhalers |
| EP4611733A1 (fr) * | 2022-11-03 | 2025-09-10 | Dana-Farber Cancer Institute, Inc. | Méthodes de traitement de l'anémie à l'aide de formotérol ou d'un sel pharmaceutiquement acceptable de celui-ci |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5795564A (en) * | 1991-04-05 | 1998-08-18 | Sepracor, Inc. | Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol |
| SG48301A1 (en) | 1991-12-18 | 1998-04-17 | Astra Ab | New combination |
| SE9802073D0 (sv) * | 1998-06-11 | 1998-06-11 | Astra Ab | New use |
| JP5392880B2 (ja) | 2000-05-22 | 2014-01-22 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| FI20002177A0 (fi) * | 2000-10-02 | 2000-10-02 | Orion Yhtymae Oyj | Uusi yhdistelmä astman hoitoon |
| FI20002215A0 (fi) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit |
| FI20002216A0 (fi) | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Yhdistelmäpartikkelit astman hoitoon |
| IL163843A0 (en) | 2002-03-01 | 2005-12-18 | Chiesi Farma Spa | Formoterol superfine formulation |
| EP1982709A1 (fr) * | 2007-04-19 | 2008-10-22 | CHIESI FARMACEUTICI S.p.A. | Utilisation d'une composition comportant du formotérol et du dipropionate de béclométhasone pour la prévention ou le traitement d'une condition aiguë de l'asthme |
-
2007
- 2007-04-19 EP EP07007930A patent/EP1982709A1/fr not_active Withdrawn
-
2008
- 2008-04-16 DK DK08748930.8T patent/DK2146704T3/en active
- 2008-04-16 KR KR1020097019229A patent/KR20100014408A/ko not_active Abandoned
- 2008-04-16 MX MX2009010851A patent/MX2009010851A/es active IP Right Grant
- 2008-04-16 PL PL16152451T patent/PL3034073T3/pl unknown
- 2008-04-16 ES ES08748930.8T patent/ES2568497T3/es active Active
- 2008-04-16 MY MYPI20094314A patent/MY169579A/en unknown
- 2008-04-16 HR HRP20160588TT patent/HRP20160588T1/hr unknown
- 2008-04-16 CA CA002684539A patent/CA2684539A1/fr not_active Abandoned
- 2008-04-16 BR BRPI0809800-0A2A patent/BRPI0809800A2/pt not_active Application Discontinuation
- 2008-04-16 JP JP2010503394A patent/JP5492072B2/ja active Active
- 2008-04-16 EP EP16152451.7A patent/EP3034073B1/fr active Active
- 2008-04-16 ES ES16152451T patent/ES2740103T3/es active Active
- 2008-04-16 HU HUE08748930A patent/HUE029263T2/en unknown
- 2008-04-16 KR KR1020157017841A patent/KR101621676B1/ko active Active
- 2008-04-16 RS RS20160439A patent/RS54874B1/sr unknown
- 2008-04-16 PL PL08748930.8T patent/PL2146704T3/pl unknown
- 2008-04-16 AU AU2008241045A patent/AU2008241045C1/en active Active
- 2008-04-16 UA UAA200909905A patent/UA100237C2/uk unknown
- 2008-04-16 GE GEAP200811515A patent/GEP20145999B/en unknown
- 2008-04-16 KR KR1020157005890A patent/KR101668203B1/ko active Active
- 2008-04-16 CN CN200880012407.9A patent/CN101657191B/zh active Active
- 2008-04-16 SI SI200831597A patent/SI2146704T1/sl unknown
- 2008-04-16 TR TR2019/09857T patent/TR201909857T4/tr unknown
- 2008-04-16 WO PCT/EP2008/003012 patent/WO2008128685A1/fr not_active Ceased
- 2008-04-16 EA EA200901201A patent/EA018589B1/ru not_active IP Right Cessation
- 2008-04-16 ME MEP-2009-315A patent/ME00945B/fr unknown
- 2008-04-16 NZ NZ580526A patent/NZ580526A/en unknown
- 2008-04-16 EP EP08748930.8A patent/EP2146704B1/fr active Active
- 2008-04-21 US US12/106,493 patent/US20080261932A1/en not_active Abandoned
-
2009
- 2009-09-24 TN TNP2009000390A patent/TN2009000390A1/fr unknown
- 2009-10-13 CO CO09113200A patent/CO6220945A2/es not_active Application Discontinuation
- 2009-10-15 MA MA32284A patent/MA31315B1/fr unknown
- 2009-10-19 IL IL201632A patent/IL201632A/en active IP Right Grant
-
2013
- 2013-10-18 JP JP2013217531A patent/JP2014005312A/ja not_active Withdrawn
-
2016
- 2016-04-14 CY CY20161100313T patent/CY1117568T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE449081T1 (de) | Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen | |
| TNSN01053A1 (fr) | Compositions nouvelles comprenant un agoniste partiel des recepteurs de nicotine et un agent analgesique | |
| EP1551369A4 (fr) | Therapie de combinaison pour le traitement de troubles fibrosants | |
| NO20033862L (no) | Fremgangsmåte for prevensjon eller terapi av inflammatoriske eller autoimmune lidelser ved administrering av integrin-alfa-beta3-antagonisteri kombinasjonmed andre profylaktiske eller terapeutiske midler | |
| SG153836A1 (en) | Combination of glycopyrrolate and a beta2 adrenoceptor agonist | |
| BR0008276A (pt) | Combinações de formoterol e propionato de fluticasona para asma | |
| NO20030337D0 (no) | Fremgangsmåte til å behandle symptomer på vanlig forkjölelse, allergisk rhinitt, og infeksjoner i respirasjonstrakten | |
| EA200100937A1 (ru) | Способы и композиции, использующие (-)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов | |
| EA200100936A1 (ru) | Способы и композиции, использующие (+)-норцисаприд в комбинации с ингибиторами протонных насосов или антагонистами h2-рецепторов | |
| MA32462B1 (fr) | Dronedarone dans le traitement prophylactique de la fibrillation auriculaire permanente | |
| NO20060328L (no) | Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser | |
| NO20082894L (no) | Metode for behandling av kognitiv dysfunksjon | |
| WO2003065987A3 (fr) | Inhibiteurs de granzyme b | |
| TN2009000390A1 (en) | Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma | |
| MXPA05011858A (es) | Agentes terapeuticos que comprenden un agente antiagiongenico en combinacion con un inhibidor src y su uso terapeutico. | |
| Kim | Deep vein thrombosis prophylaxis after total hip arthroplasty in Asian patients | |
| BR0107960A (pt) | Tratamento de condições alérgicas e inflamatórias | |
| CA2364178A1 (fr) | N-benzenesulfonyl-l-prolines utilisees comme antagonistes de la bradykinine | |
| YU57803A (sh) | Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja | |
| MA31902B1 (fr) | Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque | |
| SE0300445D0 (sv) | New combination | |
| DE60008590D1 (de) | Zusammensetzungen von adenosin a1 agonisten und cox2-hemmern | |
| DE60014429D1 (de) | Zusammensetzungen von adenosin a1 agonisten und 5ht3 agonisten | |
| HRP20050579B1 (hr) | Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol | |
| NO20041595L (no) | Ny kombinasjon bestaende av en PDE4 inhibitor eller en PDE3/4 inhibitor i kombinasjon med en leukotrienreseptorantagonist for behandling av luftveislidelser |